Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 583 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer September 2, 2020 ESMO Congress 2023, 20-24 October 2023 Madrid, Spain October 6, 2023 What could DeepMind ‘solving’ the protein folding problem mean for cancer... December 23, 2020 Load more HOT NEWS Combination of Azacitidine and Venetoclax in Previously Untreated AML Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and... A peek behind the scenes: Just how are our funding decisions... Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular...
